To the Editor Ms Hua and colleagues1 compared 2002-2013 trends in diabetes drug expenditures, particularly insulins, using the Medical Expenditure Panel Survey (MEPS). We note important limitations to their analysis and conclusions. The findings revealed recent dynamic changes in insurance benefit design as higher cost exposure shifts to consumers, but the authors overstated price and did not consider significant changes in diabetes care and the US insurance landscape during the study period.
Alatorre C, Schultz EH, Nelson DR. Cost of Antihyperglycemic Medications in the United States. JAMA. 2016;316(6):665. doi:10.1001/jama.2016.8587